Compare IBP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBP | DNTH |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.5B |
| IPO Year | 2014 | 2018 |
| Metric | IBP | DNTH |
|---|---|---|
| Price | $240.97 | $115.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $266.14 | $121.00 |
| AVG Volume (30 Days) | 353.1K | ★ 751.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | ★ 6.70 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $2,970,800,000.00 | $2,036,000.00 |
| Revenue This Year | $1.96 | N/A |
| Revenue Next Year | $4.32 | $29.48 |
| P/E Ratio | $64.75 | ★ N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $193.11 | $20.71 |
| 52 Week High | $349.00 | $116.47 |
| Indicator | IBP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 61.15 |
| Support Level | $232.57 | $79.27 |
| Resistance Level | $253.51 | N/A |
| Average True Range (ATR) | 11.26 | 5.91 |
| MACD | 0.84 | -0.05 |
| Stochastic Oscillator | 61.43 | 93.10 |
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is derived from Installation segment.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.